HALEOS LABS
|
|
| BOM : 540679     NSE : HALEOSLABS     | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Jun 12,2026 |
|
Price(EOD): ₹ 1,356.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 406.80 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| HALEOS LABS | 0.4% | -16.1% | -18.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | -0.9% | 6.8% |
| DIVIS LABORATORIES | 1.8% | -2.3% | 1.5% |
| TORRENT PHARMACEUTICALS | 3.7% | 6.5% | 44.9% |
| CIPLA | 0% | 4.7% | -8% |
| DR REDDYS LABORATORIES | -0.2% | 0.7% | -3.4% |
| MANKIND PHARMA | 0.9% | -1.2% | 0.8% |
| LUPIN | 1.8% | 3.5% | 13.8% |
| ZYDUS LIFESCIENCES | 1.6% | 17.6% | 15.2% |
FUNDAMENTAL ANALYSIS OF HALEOS LABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF HALEOS LABS
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
23.03
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 17.80 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 2.09
P/B Calculated based on Book Value of Rs 196.56 Cr
[Latest Year - Mar2025 - Consolidated Results ] 1.23
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 333.80 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
54% 111% 101% |
SHARE PRICE MOMENTUM OF HALEOS LABS
HALEOS LABS vs SENSEX
DEBT OF HALEOS LABS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.4 0.5 0.52 0.47 |
0.43 0.55 0.59 0.52 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF HALEOS LABS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF HALEOS LABS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-20.73% -70.39% -89.68% -94.83% |
-15.68% -43.94% -76.94% -90.12% |
| QtrlyTrend |
-8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
HALEOS LABS related INDICES
You may also like the below Video Courses
FAQ about HALEOS LABS
Is HALEOS LABS good for long term investment?
As on Jun 12,2026, the Fundamentals of HALEOS LABS look Poor and hence it may not be good for long term investment ! See Financial Performance of HALEOS LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is HALEOS LABS UnderValued or OverValued?
As on Jun 12,2026, HALEOS LABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of HALEOS LABS ?
As on Jun 12,2026, the Intrinsic Value of HALEOS LABS is Rs. 673.49 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 880.22
Fair Value [Median EV / Sales Model] : Rs. 642.90
Fair Value [Median Price / Sales Model] : Rs. 673.49
Estimated Median Fair Value of HALEOS LABS : Rs. 673.49
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.